2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Indoleamine 2,3-Dioxygenase (IDO)

Indoleamine 2,3-Dioxygenase (IDO)

Indoleamine 2,3-Dioxygenase (IDO)

Related Products

PDF 0.8 MB

Indoleamine 2, 3-dioxygenase (IDO) is an inflammatory cytokine-inducible rate-limiting enzyme of the tryptophan (Trp) catabolism, which is involved in the inhibition of intracellular pathogen replication as well as in immunomodulation. To date, three types of tryptophan-metabolizing enzymes have been identified: IDO1, IDO2 and tryptophan 2,3-dioxygenase 2.

IDO is an intracellular enzyme that is constitutively expressed in several human and mouse cells. Being present in innate immune cells, such as Mos and dendritic cells (DCs), IDO catalyzes the initial rate-limiting step of tryptophan (Trp) catabolism, thus leading to the production of immunoregulatory catabolites (collectively known as kynurenines).

The IDO gene promoter contains multiple sequence elements that confer responsiveness to proinflammatory mediators, thereby demonstrating the strong correlation between inflammation and induced IDO expression.

Indoleamine 2,3-Dioxygenase (IDO) Isoform Specific Products:

Indoleamine 2,3-Dioxygenase (IDO) Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-146673
    IDO1/TDO-IN-2
    		Inhibitor
    IDO1/TDO-IN-2 (Compound 1) is a potent inhibitor of IDO1/TDO with IC50s of 0.1 and 0.07 μM. IDO1/TDO-IN-2 has the potential for the research of cancer diseases.
    IDO1/TDO-IN-2
  • HY-142933
    IDO-IN-16
    		Inhibitor
    IDO-IN-16 (compound 5) is an IDO inhibitor, with an IC50 of 36 nM.
    IDO-IN-16
  • HY-148572
    NAMPT/IDO1-IN-1
    		Inhibitor
    NAMPT/IDO1-IN-1 is an orally active dual inhibitor of NAMPT and IDO1 with IC50s of 57.7 nM and 233 nM, respectively. NAMPT/IDO1-IN-1 blocks NAD+ biosynthesis, inhibits proliferation and migration of Paclitaxel (HY-B0015)- and FK866 (HY-50876)-resistant NSCLC cell lines (A549/R cells). NAMPT/IDO1-IN-1 has shown antitumor effects in mice and enhanced A549/R cell sensitivity to paclitaxel.
    NAMPT/IDO1-IN-1
  • HY-177783
    iDeg-1
    		Degrader
    iDeg-1 is a molecular glucose degrading agent that targets the IDO1 protein. iDeg-1 relies on the ubiquitin-proteasome degradation pathway mediated by its natural E3 ligase KLHDC3. iDeg-1 can be used for cancer research.
    iDeg-1
  • HY-P4149
    Imsamotide
    		Inhibitor
    Imsamotide (IDO194-214) is a Indoleamine 2,3-Dioxygenase (IDO) peptide with sequences of DTLLKALLEIASCLEKALQVF, the IDO194-214. Imsamotide is also an immunological agent for active immunization, as well as an antineoplastic agent.
    Imsamotide
  • HY-146261
    HI5
    		Inhibitor
    HI5 is a potent tublin and IDO inhibitor, with an IC50 value of 70 nM in HeLa cells. HI5 inhibit IDO expression and decrease kynurenine production, leading to stimulating T cells activation and proliferation. HI5 can inhibit tubulin polymerization and cell migration, cause G2/M phase arrest, and induce apoptosis via the mitochondrial dependent apoptosis pathway and cause reactive oxidative stress generation in HeLa cells. HI5 can be used for researching anticancer.
    HI5
  • HY-146215
    IDO1-IN-20
    Hy-146215 is an enzyme that catalyzes the oxidative metabolism of tryptophan. It can immunosuppress tumors in the tumor microenvironment.
    IDO1-IN-20
  • HY-149227
    IDO1-IN-21
    		Inhibitor
    IDO1-IN-21 (compound 10m) is an IDO1 inhibitor (IC50 = 0.64 μM). IDO1-IN-21 effectively inhibits tumor growth in mice.
    IDO1-IN-21
  • HY-173067
    IDO1 ligand-1
    IDO1 ligand-1 is the target protein ligand of PROTAC NU227326 (HY-173066). NU227326 can be used to degrade IDO1.
    IDO1 ligand-1
  • HY-178479
    IDO1-IN-30
    		Inhibitor
    IDO1-IN-30 (Compound (R)-100) is a potent and highly selective IDO1 inhibitor. IDO1-IN-30 has an IC50 of 4.8 nM to IDO1 in SKOV3 cells. IDO1-IN-30 does not show significant cytotoxicity at 25 µM in HepG2 cells. IDO1-IN-30 can eliminate inhibition of CYP450 enzymes (such as 3A4, 2C9, 2D6). IDO1-IN-30 can be used for research on cancer and inflammatory conditions.
    IDO1-IN-30
  • HY-144273
    IDO1-IN-13
    		Inhibitor
    IDO1-IN-13 (compound 27a) is a potent IDO1 inhibitor with an IC50 of 61.6 nM. IDO1-IN-13 has cellular IDO1 inhibition (HeLa EC50= 30 nM). IDO1-IN-13 decreases 51% of the kyn/trp ratio in SK-OV-3 xenograft tumor tissues.
    IDO1-IN-13
  • HY-158334
    NDs-IN-1
    		Inhibitor
    (Neurodegenerative diseases) NDs-IN-1 (Compound 3g) inhibits the activities of key enzymes such as hBACE-1, hAChE and hMAO-B. NDs-IN-1 is a novel non-covalent multi-target inhibitor. NDs-IN-1 is mainly used in the study of neurodegenerative diseases.
    NDs-IN-1
  • HY-177785
    iDeg-6
    		Degrader
    iDeg-6 is a selective molecular glue degrader that targets IDO1 with a DC50 of 6.5 nM. iDeg-6 can competitively bind to the heme binding site of apo-IDO1, preventing heme binding and inhibiting the enzymatic reaction that converts tryptophan into kynurenine by IDO1 (IC50 = 1.6 μM). iDeg-6 can be used for the researches of cancer, infection and neurological disease, such as melanoma.
    iDeg-6
  • HY-W770206
    IDO-IN-7-d10
    IDO-IN-7-d10 (NLG-919 analogue-d10; GDC-0919 analogue-d10) is the deuterium labeled IDO-IN-7 (HY-13983). IDO-IN-7 (NLG-919 analogue) is a a potent IDO1 inhibitor with an IC50 of 38 nM.
    IDO-IN-7-d<sub>10</sub>
  • HY-144778
    IDO1/TDO-IN-1
    		Inhibitor
    IDO1/TDO-IN-1 (30) is a potent dual IDO1 (uncompetitive, Ki of 0.23 μM) and TDO (competitive, Ki of 0.73 μM) inhibitor. IDO1/TDO-IN-1 (30) significantly promotes cell apoptosis through the potential mitochondria-mediated Bcl-2/Bax pathway.
    IDO1/TDO-IN-1
  • HY-163520
    IDO1-IN-24
    		Inhibitor
    IDO1-IN-24 (compound 2c) inhibits IDO1 production in cell-based assay with an IC50 value of 17 μM.
    IDO1-IN-24
  • HY-173023
    IDOi-Pt(IV) prodrug-1
    		Inhibitor
    IDOi-Pt(IV) prodrug-1 (Compound 10) is an IDOi-Pt(IV) prodrug. IDOi-Pt(IV) prodrug-1 inhibits IDO expression. IDOi-Pt(IV) prodrug-1 induces apoptosis, decreases the mitochondrial membrane potential, inhibits tumor cell migration and invasion. IDOi-Pt(IV) prodrug-1 induces reactive oxygen species-mediated endoplasmic reticulum stress and secretion of damage-associated molecular patterns (DAMPs), thereby presenting immunogenic cell death (ICD) effects. IDOi-Pt(IV) prodrug-1 has high-efficiency and low-toxicity antitumor effects compared to Cisplatin (HY-17394).
    IDOi-Pt(IV) prodrug-1
  • HY-184040
    TDO-IN-3
    		Inhibitor
    TDO-IN-3 (compound 20) is an IDO1/TDO inhibitor with IC50 values of 4.12 and 0.12 μM, respectively.
    TDO-IN-3
  • HY-154387
    1-Isopropyltryptophan
    		Inhibitor
    1-Isopropyltryptophan (1-IsoPT) is a IDO1 inhibitor. 1-Isopropyltryptophan decreases the expression of IFN-γ stimulated ID0-1 and ID0-2 mRNA.
    1-Isopropyltryptophan
  • HY-175182
    IDO1-IN-27
    		Inhibitor
    IDO1-IN-27 (Compound I-1) is a Indoleamine 2,3-Dioxygenase 1 (IDO1) inhibitor with an IC50 of 0.3951  μM for recombinant hIDO1. IDO1-IN-27 also inhibits hIDO1 expression in HeLa cells (EC50: 62 nM). IDO1-IN-27 effectively stimulates T cell proliferation by reducing the mRNA expression of pro-inflammatory factors (TNF-α, IL-6, and IL-1β) while concurrently inhibiting LLC cells growth.
    IDO1-IN-27
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
Indoleamine 2,3-Dioxygenase (IDO) Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.